Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Oogenesis02:07

Oogenesis

In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
Disorders of the Female Reproductive System01:24

Disorders of the Female Reproductive System

The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
Ovaries01:26

Ovaries

The ovaries are roughly the size of almonds and measure approximately 2 to 3 centimeters in length. These paired structures are situated within the pelvic region and are anchored by the mesovarium—a peritoneal extension that also connects them to the wider structure of the broad ligament. The support system extends to the suspensory ligament, housing blood and lymphatic vessels. In addition, the ovarian ligament tethers the ovaries to the uterus.
On the ovarian surface, a layer of cuboidal...
Ovarian Cycle01:27

Ovarian Cycle

The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle length...
Hormonal Control of the Ovarian Cycle01:30

Hormonal Control of the Ovarian Cycle

The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle.  At puberty, GnRH secretion increases in both frequency and...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Whole genome sequencing of pre-treatment and post-treatment locally advanced rectal cancer using long and short read technologies.

Scientific reports·2026
Same author

RETRACTED: Richards et al. Protein Tyrosine Phosphatase Non-Receptor 11 (<i>PTPN11</i>/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC). <i>Int. J. Mol. Sci.</i> 2023, <i>24</i>, 10545.

International journal of molecular sciences·2026
Same author

A pipeline of machine learning-driven multi-modal data fusion methods for prognostic risk analysis in bevacizumab-treated metastatic colorectal cancer.

Scientific reports·2026
Same author

Case Report: Whole-genome sequencing of urothelial carcinoma in an adult patient with CLOVES syndrome reveals a lack of <i>PIK3CA</i> mutation and a genomic landscape consistent with urothelial carcinoma.

Frontiers in oncology·2026
Same author

Early termination of NCT04617067, a phase II, open label, clinical trial of oral paricalcitol in combination with gemcitabine and NAB-paclitaxel therapy in advanced pancreatic cancer.

BMC cancer·2026
Same author

Dose Adjusted Neoadjuvant Paclitaxel, Carboplatin, Trastuzumab and Pertuzumab in Women With HER2 Positive Early Breast Cancer.

Clinical breast cancer·2025

Video Experimental Relacionado

Updated: Jun 19, 2026

An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum
05:42

An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum

Published on: January 26, 2024

Cáncer de ovario El cáncer de ovario.

Bryan T Hennessy1, Robert L Coleman, Maurie Markman

  • 1Department of Gynecologic Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Lancet (London, England)
|October 2, 2009
PubMed
Resumen

El tratamiento estándar para el cáncer de ovario epitelial implica cirugía y quimioterapia. Si bien los tratamientos iniciales son efectivos, la recurrencia es común, lo que requiere la investigación de nuevas terapias para mejorar la supervivencia y los resultados de los pacientes.

Más Videos Relacionados

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

Transplantation Into the Mouse Ovarian Fat Pad
09:25

Transplantation Into the Mouse Ovarian Fat Pad

Published on: September 7, 2016

Videos de Experimentos Relacionados

Last Updated: Jun 19, 2026

An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum
05:42

An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum

Published on: January 26, 2024

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

Transplantation Into the Mouse Ovarian Fat Pad
09:25

Transplantation Into the Mouse Ovarian Fat Pad

Published on: September 7, 2016

Área de la Ciencia:

  • Oncología Ginecológica Oncología Ginecológica.
  • Oncología médica Oncología médica.
  • Oncología Quirúrgica Oncología Quirúrgica.

Sus antecedentes:

  • El manejo del cáncer de ovario epitelial (EOC, por sus siglas en inglés) por lo general incluye la estadificación quirúrgica, el desbloqueo tumoral y la quimioterapia (carboplatino/paclitaxel).
  • El desbloqueo quirúrgico óptimo a <1 cm de enfermedad residual se correlaciona con mejores resultados para los pacientes.
  • La mayoría de los pacientes (75%) presentan enfermedad avanzada (etapa III/IV), y a pesar de las tasas de respuesta inicial >80%, la recurrencia es casi universal.

Objetivo del estudio:

  • Revisar el manejo estándar del cáncer de ovario epitelial.
  • Para resaltar los desafíos de la recurrencia del tumor en etapas avanzadas.
  • Discutir posibles futuras estrategias terapéuticas para mejorar los resultados de los pacientes.

Principales métodos:

  • Revisión de los protocolos quirúrgicos y quimioterapéuticos estándar para el cáncer de ovario epitelial.
  • Análisis de los factores de pronóstico, incluida la extensión del desbloqueo quirúrgico.
  • Exploración de modalidades de tratamiento emergentes y técnicas de administración de fármacos.

Principales resultados:

  • El tratamiento estándar ofrece un beneficio inicial, pero a menudo es seguido por la recurrencia del tumor dentro de una mediana de 15 meses.
  • Los tratamientos de segunda línea pueden paliar los síntomas y mejorar la calidad de vida, pero no son curativos.
  • La recurrencia del tumor sigue siendo un desafío significativo en el cáncer de ovario epitelial avanzado.

Conclusiones:

  • Los avances en el cribado, la comprensión de la patogénesis molecular, las terapias dirigidas (por ejemplo, bevacizumab) y la administración intraperitoneal de medicamentos son cruciales para mejorar los resultados.
  • La investigación futura debe centrarse en nuevas estrategias terapéuticas para superar la resistencia al tratamiento y prevenir la recurrencia.
  • Se esperan mejores resultados en pacientes con cáncer epitelial de ovario a través de enfoques integrados que combinan detección temprana y modalidades de tratamiento avanzado.